oncology
Breast Cancer

Prof Geoff Lindeman: Venetoclax plus fulvestrant in ER+/HER2- breast cancer

Adding the BCL2 inhibitor venetoclax to fulvestrant  did not improve clinical benefit rates (CBR) or PFS in women with oestrogen receptor-positive, HER2-negative locally advanced breast cancer compared to fulvestrant alone, new research from Australia reveals. Presenting the findings from the phase II VERONICA trial at ASCO this week lead investigator Professor Geoffrey Lindeman from the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic